Kanbayashi Yuko, Ishizuka Yuichi, Shimizu Mayumi, Sawa Shohei, Yabe Katsushige, Uchida Mayako
Department of Education and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki, Osaka, 569-1094, Japan.
Department of Pharmacy, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
Support Care Cancer. 2022 Jul;30(7):5831-5836. doi: 10.1007/s00520-022-07002-9. Epub 2022 Mar 31.
To identify risk factors for opioid-induced constipation (OIC).
This study retrospectively analyzed 175 advanced cancer patients who were receiving pain treatment with opioids and were newly prescribed laxatives for OIC at Seirei Hamamatsu General Hospital between November 2016 and June 2021. For the regression analysis of factors associated with OIC, variables were extracted manually from clinical records. The effect of newly prescribed laxatives for OIC was evaluated as "effective" in cases where the number of spontaneous bowel movements increased at least once in the first 3 days. The OIC was defined based on Rome IV diagnostic criteria. Multivariate logistic regression analysis was performed to identify risk factors for OIC. Optimal cutoff thresholds were determined using receiver operating characteristic analysis. Values of P < 0.05 (two-tailed) were considered significant.
Significant factors identified included body mass index (BMI) (odds ratio [OR] = 0.141, 95% confidence interval [CI] = 0.027-0.733; P = 0.020), chemotherapy with taxane within 1 month of evaluation of laxative effect (OR = 0.255, 95% CI = 0.068-0.958; P = 0.043), use of naldemedine (OR = 2.791, 95% CI = 1.220-6.385; P = 0.015), and addition or switching due to insufficient prior laxatives (OR = 0.339, 95% CI = 0.143-0.800; P = 0.014).
High BMI, chemotherapy including a taxane within 1 month of evaluation of laxative effect, no use of naldemedine, and addition or switching due to insufficient prior laxatives were identified as risk factors for OIC in advanced cancer patients with cancer pain.
确定阿片类药物引起的便秘(OIC)的危险因素。
本研究回顾性分析了2016年11月至2021年6月期间在静冈清水综合医院接受阿片类药物止痛治疗且新开具治疗OIC泻药的175例晚期癌症患者。为了对与OIC相关的因素进行回归分析,从临床记录中手动提取变量。在新开具的治疗OIC的泻药使用后的前3天内,自发排便次数至少增加一次的病例被评估为“有效”。OIC根据罗马IV诊断标准定义。进行多因素逻辑回归分析以确定OIC的危险因素。使用受试者工作特征分析确定最佳截断阈值。P值<0.05(双侧)被认为具有统计学意义。
确定的显著因素包括体重指数(BMI)(比值比[OR]=0.141,95%置信区间[CI]=0.027 - 0.733;P=0.020)、在评估泻药效果前1个月内使用紫杉烷进行化疗(OR=0.255,95%CI=0.068 - 0.958;P=0.043)、使用纳洛酮(OR=2.791,95%CI=1.220 - 6.385;P=0.015)以及因先前泻药不足而增加或更换泻药(OR=0.339,95%CI=0.143 - 0.800;P=0.014)。
高BMI、在评估泻药效果前1个月内使用包括紫杉烷在内的化疗、未使用纳洛酮以及因先前泻药不足而增加或更换泻药被确定为患有癌痛的晚期癌症患者发生OIC的危险因素。